Bristol Myers Squibb Bristol Myers Squibb Unveils Promising Sotyktu Results for Psoriatic Arthritis and Lupus at ACR Conference Bristol Myers Squibb has unveiled new data from late-breaking clinical studies highlighting the promise of Sotyktu (deucravacitinib) in treating both psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE). These findings, from the pivotal Phase 3 POETYK PsA-1 trial and integrated Phase 2 PAISLEY-SLE and long-term extension studies. Psoriati
